Abstract
G protein-coupled CB1 cannabinoid receptors are found in high density in the nervous system. CB1 cannabinoid receptors have the ability to change conformation between inactive and active receptor states in the absence of agonists. The ability to adopt an active conformation in the absence of agonists results in constitutive receptor signaling. Inverse agonists reverse the constitutive activity of the receptor in the absence of agonists also antagonize receptor activity due to the presence of agonists. This dual effect of the CB1 cannabinoid receptor inverse agonist SR141716A is a result of its ability to bind both inactive and active receptors, but with a relatively higher affinity for the inactive receptor. The higher affinity of SR141716A for the inactive receptor is due to its ability to hydrogen bond to lysine 3.28 in transmembrane helix 3, a residue available to SR141716A only in the inactive state.
Keywords: Protein-Coupling, transmembrane, SR141716A
Current Neuropharmacology
Title: Cannabinoid Receptor G Protein-Coupling and Inverse Agonism
Volume: 2 Issue: 1
Author(s): Deborah L. Lewis
Affiliation:
Keywords: Protein-Coupling, transmembrane, SR141716A
Abstract: G protein-coupled CB1 cannabinoid receptors are found in high density in the nervous system. CB1 cannabinoid receptors have the ability to change conformation between inactive and active receptor states in the absence of agonists. The ability to adopt an active conformation in the absence of agonists results in constitutive receptor signaling. Inverse agonists reverse the constitutive activity of the receptor in the absence of agonists also antagonize receptor activity due to the presence of agonists. This dual effect of the CB1 cannabinoid receptor inverse agonist SR141716A is a result of its ability to bind both inactive and active receptors, but with a relatively higher affinity for the inactive receptor. The higher affinity of SR141716A for the inactive receptor is due to its ability to hydrogen bond to lysine 3.28 in transmembrane helix 3, a residue available to SR141716A only in the inactive state.
Export Options
About this article
Cite this article as:
Lewis L. Deborah, Cannabinoid Receptor G Protein-Coupling and Inverse Agonism, Current Neuropharmacology 2004; 2 (1) . https://dx.doi.org/10.2174/1570159043476891
DOI https://dx.doi.org/10.2174/1570159043476891 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Inhibition of Brain Phospholipase A2 by Antimalarial Drugs: Implications for Neuroprotection in Neurological Disorders
Medicinal Chemistry Reviews - Online (Discontinued) The Innate Immunity in Alzheimer Disease- Relevance to Pathogenesis and Therapy
Current Pharmaceutical Design The Association between Regular Cannabis Exposure and Alterations of Human Brain Morphology: An Updated Review of the Literature
Current Pharmaceutical Design P2X1 and P2X2 Receptors in the Central Nervous System as Possible Drug Targets
CNS & Neurological Disorders - Drug Targets Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition
Current Medicinal Chemistry - Central Nervous System Agents Serotonin and its Receptors in the Human CNS with New Findings - A Mini Review
Current Medicinal Chemistry Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Selective Thyroid Hormone Receptor Modulators
Current Topics in Medicinal Chemistry A Closer Look at α-Secretase
Current Alzheimer Research Neurotoxicity by Synthetic Androgen Steroids: Oxidative Stress, Apoptosis, and Neuropathology: A Review
Current Neuropharmacology Perspectives and New Aspects of Metalloproteinases’ Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine
Current Medicinal Chemistry HIV-1 gp120 and Drugs of Abuse: Interactions in the Central Nervous System
Current HIV Research The Role of the PACAP Signaling System in Depression
Current Pharmaceutical Design Anabolic Androgenic Steroids and Intracellular Calcium Signaling: A Mini Review on Mechanisms and Physiological Implications
Mini-Reviews in Medicinal Chemistry Edema-mass Ratio Based On Magnetic Resonance Imaging As A Preoperative Diagnostic Factor For Posterior Fossa Metastasis
Current Medical Imaging Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy
Current Neuropharmacology Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer’s Disease
Current Drug Targets Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Impacting Neuronal and Vascular Cellular Signal Transduction through the Metabotropic Glutamate Receptor System
Medicinal Chemistry Reviews - Online (Discontinued)